A case of giant cell myocarditis mimicking cardiac sarcoidosis successfully maintained by prednisolone and tacrolimus.

Cardiac sarcoidosis Giant cell myocarditis Immunosuppressive therapy Left ventricular dysfunction Prednisolone Tacrolimus

Journal

Journal of cardiology cases
ISSN: 1878-5409
Titre abrégé: J Cardiol Cases
Pays: Japan
ID NLM: 101549579

Informations de publication

Date de publication:
Jun 2023
Historique:
received: 16 11 2022
revised: 07 01 2023
accepted: 31 01 2023
medline: 7 6 2023
pubmed: 7 6 2023
entrez: 7 6 2023
Statut: epublish

Résumé

A 45-year-old woman with no medical history underwent pacemaker implantation for a symptomatic complete atrioventricular block. On day 6, she noticed diplopia and then fever, general malaise, and elevation of serum creatinine kinase (CK). She was transferred to our hospital on day 21. Serum CK was elevated to 4543 IU/L, and echocardiography revealed a left ventricular ejection fraction of 43 %. We diagnosed her with giant cell myocarditis (GCM) via an emergent myocardial biopsy that revealed a proliferation of lymphocytes, eosinophils, and giant cells without granulomas. Initial treatment with high doses of intravenous methylprednisolone and immunoglobulin improved her symptoms in a few days, and prednisolone was given as follow-up treatment. CK was normalized in a week and a thinning of the interventricular septum mimicking cardiac sarcoidosis (CS) occurred. On day 38, we added a calcineurin inhibitor, tacrolimus, and maintained her with a combination of prednisolone and tacrolimus at a target dose of 10-15 ng/mL. Six months after the onset, there were no signs of relapse despite the persistent mild elevation of troponin I levels. We present a case of GCM mimicking CS successfully maintained by a combination of two immunosuppressive agents. Recommended treatment for giant cell myocarditis (GCM), a potentially fatal disease, is a combination of three immunosuppressive agents. However, GCM shares many characteristics with cardiac sarcoidosis (CS), which is treated using prednisolone alone in many cases. Recent studies on GCM and CS suggest they are different spectrums of a common entity. Although they can clinically overlap, they have different progressive speeds and severities. We present a case of GCM mimicking CS successfully treated with a combination of two immunosuppressive agents.

Identifiants

pubmed: 37283907
doi: 10.1016/j.jccase.2023.01.009
pii: S1878-5409(23)00010-5
pmc: PMC10240421
doi:

Types de publication

Case Reports

Langues

eng

Pagination

258-261

Informations de copyright

© 2023 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

The authors declare no conflicts of interest associated with this manuscript.

Références

Clin Transplant. 2014 Jan;28(1):88-95
pubmed: 24325305
J Am Coll Cardiol. 2021 Mar 2;77(8):1122-1134
pubmed: 33632487
Eur J Heart Fail. 2016 Dec;18(12):1452-1458
pubmed: 27407025
ESC Heart Fail. 2020 Jun;7(3):1362-1370
pubmed: 32343481
Minerva Anestesiol. 2015 Nov;81(11):1244-61
pubmed: 25251864
N Engl J Med. 1997 Jun 26;336(26):1860-6
pubmed: 9197214
J Am Heart Assoc. 2021 Mar 16;10(6):e019415
pubmed: 33660520
Eur Heart J Case Rep. 2021 Aug 23;5(8):ytab214
pubmed: 34514299
Intern Med. 2022 Oct 1;61(19):2895-2898
pubmed: 35249924
J Am Coll Cardiol. 2003 Jan 15;41(2):322-9
pubmed: 12535829

Auteurs

Hiroki Tsuchiya (H)

Department of Cardiovascular Biology and Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

Takeshi Kashimura (T)

Department of Cardiovascular Biology and Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

Yuzo Washiyama (Y)

Department of Cardiovascular Biology and Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

Takayuki Kumaki (T)

Department of Cardiovascular Biology and Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

Mitsuhiro Watanabe (M)

Department of Cardiovascular Biology and Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

Mayumi Kase (M)

Department of Cardiovascular Biology and Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

Mitsuo Ishizuka (M)

Department of Cardiovascular Biology and Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

Ryohei Sakai (R)

Department of Cardiovascular Biology and Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

Shinya Fujiki (S)

Department of Cardiovascular Biology and Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

Tsugumi Takayama (T)

Department of Cardiovascular Biology and Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

Shiro Ishihara (S)

Department of Cardiovascular Biology and Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

Takayuki Inomata (T)

Department of Cardiovascular Biology and Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

Classifications MeSH